0001077183-23-000080.txt : 20230629 0001077183-23-000080.hdr.sgml : 20230629 20230629162138 ACCESSION NUMBER: 0001077183-23-000080 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20230626 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230629 DATE AS OF CHANGE: 20230629 FILER: COMPANY DATA: COMPANY CONFORMED NAME: NEOGENOMICS INC CENTRAL INDEX KEY: 0001077183 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-TESTING LABORATORIES [8734] IRS NUMBER: 742897368 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-35756 FILM NUMBER: 231057690 BUSINESS ADDRESS: STREET 1: 9490 NEOGENOMICS WAY CITY: FORT MYERS STATE: FL ZIP: 33912 BUSINESS PHONE: 2397680600 MAIL ADDRESS: STREET 1: 9490 NEOGENOMICS WAY CITY: FORT MYERS STATE: FL ZIP: 33912 FORMER COMPANY: FORMER CONFORMED NAME: AMERICAN COMMUNICATIONS ENTERPRISES INC DATE OF NAME CHANGE: 19990120 8-K 1 neo-20230626.htm 8-K neo-20230626
0001077183FALSE00010771832023-06-262023-06-26

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549 
 
FORM 8-K  
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported)
June 26, 2023
 
NEOGENOMICS, INC.
(Exact name of registrant as specified in its charter) 
 
Nevada
001-35756
74-2897368
(State or other jurisdiction
of incorporation)
(Commission
File Number)
(I.R.S. Employer
Identification No.)

 
9490 NeoGenomics Way,Fort Myers,Florida33912
(Address of principal executive offices)(Zip Code)
(239) 768-0600
(Registrant’s telephone number, including area code) 
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
 
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each classTrading SymbolName of each exchange on which registered
Common stock ($0.001 par value)NEOThe Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ 



Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
Board of Director Resignation
On June 26, 2023, Rachel Stahler provided NeoGenomics, Inc., a Nevada corporation (the “Company”), with notice of her resignation from the Board of Directors of the Company (the “Board”), effective immediately. Ms. Stahler’s decision to resign did not result from any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.
Board of Director Appointments
On June 26, 2023, the Board of Directors of the Company increased the size of the Board from eight to ten members and appointed Elizabeth Floegel, Neil Gunn, and Tony Zook as directors to fill the vacancies resulting from that increase and from the resignation of Ms. Stahler.
Ms. Floegel and Mssrs. Gunn and Zook will serve as members of the Board until the 2024 annual meeting of shareholders of the Company or until his or her resignation or removal and otherwise until his or her successor is elected. Ms. Floegel and Mssrs. Gunn and Zook will receive compensation for their service as independent directors consistent with the Company’s director compensation program previously disclosed in the Company’s definitive proxy statement for its 2023 annual meeting of shareholders.
Item 7.01
Regulation FD Disclosure.
On June 29, 2023, the Company issued a press release regarding the forgoing, which is attached to this Current Report on Form 8-K as Exhibit 99.1 and incorporated herein by reference.
This information shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and it shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
Item 9.01
Financial Statements and Exhibits.

(a)
Not applicable
(b)
Not applicable
(c)
Not applicable
(d)
Exhibits.
99.1
104
Cover Page Interactive Data File (embedded within the Inline XBRL document).


SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
NEOGENOMICS, INC.
Date: June 29, 2023By:/s/ Alicia C. Olivo
Name:Alicia C. Olivo
Title:General Counsel and Corporate Secretary


 EX-99.1 2 a99-1pressreleasedated6292.htm EX-99.1 Document

Exhibit 99.1
image.jpg

NeoGenomics Expands Board of Directors with Appointments of Three Independent Directors

FT. MYERS, FL / ACCESSWIRE / June 29, 2023 / NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of oncology testing and global contract research services, today announced the appointment of Elizabeth Floegel, Neil Gunn, and Tony Zook to its Board of Directors.
The Board has elected three new independent board members to join the board effective June 29, 2023. Elizabeth Floegel, Chief Information & Digital Officer of Numotion, a complex rehabilitation technology provider, will be a member of the Audit & Finance and Compliance Committees. Neil Gunn, former Chief Executive Officer of IDbyDNA, a developer of metagenomic technology for infectious disease testing and pathogen surveillance which was acquired by Illumina in 2022, will be a member of the Culture & Compensation and Nominating and Corporate Governance Committees. Tony Zook, former Chief Executive Officer of Innocoll Pharmaceuticals, a pharmaceutical manufacturing company focused on postsurgical pain management, will be a member of the Audit & Finance and Culture & Compensation Committees. The three join a strong, independent board with world-class talent and unique and differentiated skillsets.
“Elizabeth, Neil and Tony collectively bring more than 50 years of executive experience in healthcare, which will broaden the skills of our current Board, especially in the fields of digital technologies, global marketing and molecular diagnostics” said Lynn Tetrault, Chair of the Board of Directors. “We welcome Elizabeth, Neil and Tony to the board at this pivotal time for the company and look forward to working with them to drive long term, sustainable and profitable growth for the benefit of all of our stakeholders.”
“Our new board members are seasoned business leaders whose public company experience and financial acumen will be valuable to our Board as the company continues to execute on its vision,” said Chris Smith, Chief Executive Officer of NeoGenomics.
New Independent Director Biographies
Elizabeth Floegel has a track record for successfully leading technology and organizational transformation in highly matrixed environments. As Chief Information & Digital Officer of Numotion, Elizabeth is managing a significant digital and cybersecurity transformation with the strategic use of data and technology to drive value creation by creating efficient and compliant operations. Before joining Numotion, Ms. Floegel was the Global Vice President of Business Technology at Allergan (now part of Abbvie). In her time at Allergan, she led the technology portfolio across global commercial, retail, digital products and marketing. Ms. Floegel’s earlier roles include Head of Commercial and Digital Technology for Regeneron Pharmaceuticals and Global Vice President of Commercial Technology for Baxter Healthcare.
Neil Gunn is a veteran Diagnostics senior executive with expertise in company organization to maximize efficiencies with a focus on value generators to drive growth. Most recently, Neil was the Chief Executive Officer of IDbyDNA, which was acquired by Illumina in 2022. Prior to that, Dr. Gunn was President of Roche Sequencing Solutions (RSS), where he grew the organization from early initial concepts to over 900 employees across three continents while integrating nine acquisitions into one with a common vision


and strategy. Before RSS, Dr. Gunn was Head of Global Business for Roche Molecular Diagnostics (RMD) and was responsible of the development and execution of strategic plan that launched over 140 major assay, instrument, and software launches over six years. Neil’s earlier roles include Vice President Commercial Operations for CaridianBCT and Vice President of Commercial Operations – Americas for Novartis Diagnostics.
Tony Zook has significant experience as a brand and marketing executive with a focus on managing interface between commercial and research and development aspects of an organization. Prior to serving as Chief Executive Officer of Innocoll Pharmaceuticals, Tony was Executive Vice President, Commercial Operations of AstraZeneca (AZ) where he held global P&L responsibility for all of AZ’s brands and markets. Under Tony’s leadership, AZ commercialized ten brands, each in excess of $1 billion in sales. Tony was also responsible for MedImmune, AZ’s global biologics business. He also chaired the Commercial Investment Board, which identified and approved critical investments company-wide, including investments in plants, markets, and technology. Earlier in his career at AZ, Mr. Zook held various positions including CEO of North America and VP of Sales, where he helped lead the integrations of Astra US, Astra Merck, and Zeneca. Prior to joining AZ, Mr. Zook spent 14 years with Berlex Laboratories in a variety of positions.
About NeoGenomics, Inc.
NeoGenomics, Inc. specializes in cancer genetics testing and information services, providing one of the most comprehensive oncology-focused testing menus in the world to help physicians diagnose and treat cancer.
NeoGenomics is committed to connecting patients with life altering therapies and trials. We believe that, together, with our partners, we can help patients with cancer today and the next person diagnosed tomorrow. In carrying out these commitments, NeoGenomics adheres to all applicable state and federal data protection laws, provides transparency and choice to patients regarding the handling and use of their data through expressed authorizations and our Notice of Privacy Practices, and has invested in leading technologies to ensure the data we maintain is secured at all times.
Forward Looking Statements
This press release includes forward-looking statements. Each forward-looking statement contained in this press release is subject to a number of risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statement. Applicable risks and uncertainties include, among others, the Company's ability to identify and implement appropriate financial and operational initiatives to improve performance, to identify and recruit executive candidates, to continue gaining new customers, offer new types of tests, integrate its acquisitions and otherwise implement its business plan, and the risks identified under the heading "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2022 filed with the SEC on February 24, 2023 as well as other information previously filed with the SEC. The forward-looking statements in this press release speak only as of the date of this document (unless another date is indicated), and we undertake no obligation to update or revise any of these statements.
NeoGenomics, Inc.
Kendra Sweeney
Vice President, Investor Relations and Communications
Kendra.Sweeney@neogenomics.com
T: +1-239-877-7474

 EX-101.SCH 3 neo-20230626.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 neo-20230626_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Security Exchange Name Security Exchange Name Title of 12(b) Security Title of 12(b) Security Written Communications Written Communications Local Phone Number Local Phone Number Trading Symbol Trading Symbol Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity Address, State or Province Entity Address, State or Province Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Document Period End Date Document Period End Date Cover [Abstract] Entity Emerging Growth Company Entity Emerging Growth Company Pre-commencement Tender Offer Pre-commencement Tender Offer Soliciting Material Soliciting Material City Area Code City Area Code Entity Address, Postal Zip Code Entity Address, Postal Zip Code Document Type Document Type Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Entity File Number Entity File Number Entity Address, City or Town Entity Address, City or Town Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Entity Registrant Name Entity Registrant Name EX-101.PRE 5 neo-20230626_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 6 image.jpg begin 644 image.jpg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end XML 7 R1.htm IDEA: XBRL DOCUMENT v3.23.2
Cover
Jun. 26, 2023
Cover [Abstract]  
Document Type 8-K
Document Period End Date Jun. 26, 2023
Entity Registrant Name NEOGENOMICS, INC.
Entity Central Index Key 0001077183
Amendment Flag false
Entity Incorporation, State or Country Code NV
Entity File Number 001-35756
Entity Tax Identification Number 74-2897368
Entity Address, Address Line One 9490 NeoGenomics Way,
Entity Address, City or Town Fort Myers,
Entity Address, State or Province FL
Entity Address, Postal Zip Code 33912
City Area Code (239)
Local Phone Number 768-0600
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common stock ($0.001 par value)
Trading Symbol NEO
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
XML 8 neo-20230626_htm.xml IDEA: XBRL DOCUMENT 0001077183 2023-06-26 2023-06-26 0001077183 false 8-K 2023-06-26 NEOGENOMICS, INC. NV 001-35756 74-2897368 9490 NeoGenomics Way, Fort Myers, FL 33912 (239) 768-0600 false false false false Common stock ($0.001 par value) NEO NASDAQ false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

-8?20$3;8T.P6BP^0"X99K>]9!:G%C:^?VZH:TE[VE-S9NMQ=%A?B MTX'HE'QY%V)N:I%FGJ:QJ,';>$<-!)U4Q-Z*0CZFL6&P9:P!Q+MTFF6SU%L, M9KD8M;:X1+_)UW,#ECQ ,ZE._<]'<')O$8T.,5RMQD)HDU M75Z(\4I!K-L53,[E9C(,]L""Q1]ZUYG\M(?8,V(/'U:-Y&:6J6"%'*7?Z/6M M>CR#+@^H%7I")\!K*_#,U#88CIV,IDAO8O0]C.=0XIS_4R-5%1:PIJ+U$&3H MD<%U!D.LL8DF"=9#;E9T!N[RZ .;O\P>=0>6N=6RKV'5[+E&''\GN4/4$L#!!0 ( +*"W58D M'INBK0 /@! : >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'.UD3T. M@S ,A:\2Y0 U4*E#!4Q=6"LN$ 7S(Q(2Q:X*MR^% 9 Z=&&RGBU_[\E.GV@4 M=VZ@MO,D1FL&RF3+[.\ I%NTBB[.XS!/:A>LXEF&!KS2O6H0DBBZ0=@S9)[N MF:*'3^ 5!+ P04 " "R M@MU699!YDAD! #/ P $P %M#;VYT96YT7U1Y<&5S72YX;6RMDTU.PS 0 MA:\295LE+BQ8H*8;8 M=< %C3QJK_I-G6M+;,T[:2J 2%85-K'C>O,^>EZS> MCQ&PZ)WUV)0=47P4 E4'3F(=(GBNM"$Y2?R:MB)*M9-;$/?+Y8-0P1-XJBA[ ME.O5,[1R;ZEXZ7D;3?!-FI6.5Z*U .EK >MKBRAE#VQH%.JB]XY8: M8P*IL0,@9^O1=#%-)IXPC,^[V?S!9@K(RDT*$3FQ!'_'G2/)W55D(TADIJ]X M(;+U[/M!3EN#OI'-X_T,:3?D@6)8YL_X>\87_QO.\1'"[K\_L;S63AI_YHOA M/UY_ 5!+ 0(4 Q0 ( +*"W58'04UB@0 +$ 0 " M 0 !D;V-0&UL4$L! A0#% @ LH+=5A5*2(#N M*P( !$ ( !KP &1O8U!R;W!S+V-O&UL4$L! A0# M% @ LH+=5IE&PO=V]R:W-H965T&UL4$L! A0# M% @ LH+=5I^@&_"Q @ X@P T ( !C0P 'AL+W-T M>6QE&PO=V]R:V)O;VLN>&UL4$L! A0#% M @ LH+=5B0>FZ*M ^ $ !H ( !LA$ 'AL+U]R96QS M+W=O9(9 0 SP, M !, ( !EQ( %M#;VYT96YT7U1Y<&5S72YX;6Q02P4& / D "0 ^ @ X1, end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.2 html 1 22 1 false 0 0 false 0 false false R1.htm 0000001 - Document - Cover Sheet http://neogenomics.com/role/Cover Cover Cover 1 false false All Reports Book All Reports neo-20230626.htm a99-1pressreleasedated6292.htm neo-20230626.xsd neo-20230626_lab.xml neo-20230626_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "neo-20230626.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 22 }, "contextCount": 1, "dts": { "inline": { "local": [ "neo-20230626.htm" ] }, "labelLink": { "local": [ "neo-20230626_lab.xml" ] }, "presentationLink": { "local": [ "neo-20230626_pre.xml" ] }, "schema": { "local": [ "neo-20230626.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] } }, "elementCount": 24, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2023": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 22, "memberCustom": 0, "memberStandard": 0, "nsprefix": "neo", "nsuri": "http://neogenomics.com/20230626", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "neo-20230626.htm", "contextRef": "ifd97c4fde2b54e53b2966fd963437602_D20230626-20230626", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0000001 - Document - Cover", "menuCat": "Cover", "order": "1", "role": "http://neogenomics.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "neo-20230626.htm", "contextRef": "ifd97c4fde2b54e53b2966fd963437602_D20230626-20230626", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://neogenomics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://neogenomics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2023", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://neogenomics.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://neogenomics.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://neogenomics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://neogenomics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://neogenomics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://neogenomics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://neogenomics.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://neogenomics.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://neogenomics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://neogenomics.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://neogenomics.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://neogenomics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://neogenomics.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://neogenomics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://neogenomics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://neogenomics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://neogenomics.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://neogenomics.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://neogenomics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://neogenomics.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://neogenomics.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 15 0001077183-23-000080-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001077183-23-000080-xbrl.zip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